Get the Stockscreener App
3.65
4.29%
0.15
Fulcrum Therapeutics Inc stock is traded at $3.65, with a volume of 2.30M.
It is up +4.29% in the last 24 hours and up +4.29% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
See More
Previous Close:
$3.50
Open:
$3.47
24h Volume:
2.30M
Relative Volume:
0.99
Market Cap:
$243.21M
Revenue:
$80.00M
Net Income/Loss:
$-76.12M
P/E Ratio:
-3.1836
EPS:
-1.1465
Net Cash Flow:
$-63.88M
1W Performance:
+4.29%
1M Performance:
+4.29%
6M Performance:
-64.00%
1Y Performance:
-54.03%
1-Day Range:
$3.46
$3.785
1-Week Range:
$3.41
$3.785
52-Week Range:
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.65 | 233.22M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Initiated | JP Morgan | Overweight |
| Nov-24-25 | Initiated | Truist | Buy |
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
BlackRock Portfolio Management LLC discloses 6.0% holding in THERAPEUTICS INC (FULC) - Stock Titan
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Form 4 Fulcrum Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa
Kaplan Fox & Kilsheimer LLP Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to a Securities Investigation - NewMediaWire
Kevin Tang buys $891k of Fulcrum Therapeutics stock - Investing.com
Fulcrum Therapeutics, Inc. (FULC) gains Tang Capital as 10.4% shareholder - Stock Titan
Fulcrum Therapeutics (FULC) holder adds 249,946 shares in open-market buys - Stock Titan
Fulcrum Therapeutics (FULC) insider reports 6,663,383-share Tang Capital stake - Stock Titan
Frontier tech research, news & data - MLQ.ai
Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Fulcrum Therapeutics (FULC) Slides 3.7% as Sellers Test Key Support Near $3.45Charm Flow - dars.gov.et
Fulcrum Therapeutics Inc. (FULC) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Market ReactionRevenue Surprise History - dars.gov.et
Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66 - Stock Titan
Fulcrum Therapeutics (FULC) director awarded 32,000 stock options - Stock Titan
Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike - Stock Titan
Fulcrum Therapeutics (FULC) director granted 32,000 stock options at $3.66 strike - Stock Titan
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K. - Moomoo
After plunging 21.5% in 4 weeks, here's why the trend might reverse for Fulcrum Therapeutics (FULC) - MSN
Fulcrum Therapeutics | 8-K: Current report - Moomoo
Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcru - GuruFocus
Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan - Stock Titan
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000E Growth Benchmark - marketscreener.com
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - Eastern Progress
Price to sales forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Price to earnings forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit - Yahoo Finance
Fulcrum Therapeutics (FULC) Surges 5.26% as Biotech Momentum Builds, Testing Key ResistanceHigh Dividend Factor - dars.gov.et
[144] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan
Fulcrum Therapeutics, Inc. Actuals & Estimates (NASDAQ:FULC) - TradingView
EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan
EcoR1 Capital (FULC) reports shared control of 6.0M shares; 9.0% stake - Stock Titan
Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure - TipRanks
Fulcrum Therapeutics (FULC) details 2026 stockholder voting on directors and key proposals - Stock Titan
Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey
Fulcrum Therapeutics (FULC) Advances 1.8% as Shares Test Resistance Near $4.12Growth ETF - dars.gov.et
Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fulcrum plunges after discontinuing lead program - MSN
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securiti - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-06-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | NDAQ:FULC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):